AstraZeneca PLC Ordinary Shares (AZN) Financial Statements

AstraZeneca PLC Ordinary Shares

AZN · NYSE

No income data available for this period yet.

Analyst Estimates

Period	Consensus EPS	Low	High	Estimates	Revisions
Dec 2026	$10.22	$10.05	$10.33	6	↑1 ↓3
Dec 2027	$11.39	$11.10	$11.80	7	↑0 ↓5
Dec 2028	$12.09	$11.52	$12.41	3	↑1 ↓0
Dec 2029	$12.13	$12.13	$12.13	1	↑0 ↓0

Forward estimates are the sell-side consensus reported by Nasdaq, not a metir forecast.

Symbol: AZN
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: Europe
Exchange: NYSE

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.

Key Issues

Bullish view

A reported $400 billion combination with Bristol Myers Squibb could expand AstraZeneca’s pharmaceutical portfolio and strengthen its competitive position across major therapeutic areas.

Bearish view

The scale of the reported transaction could create substantial execution, financing, regulatory and integration risks, potentially destroying value even if the strategic rationale is sound.

Analyst Consensus

See all

Buy

12 analysts

$162

Current

—

Low

$214

Average

—

High

Average target implies +32.09% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Amgen Inc.AMGN · NASDAQ-GS$406.14